Spero Therapeutics (SPRO) Insider Smith Buys 20,000 Shares
Insider Cynthia Smith added 20,000 shares of Spero Therapeutics on June 23, 2026, joining a wave of insider purchases.
Reviewed by automated data checks against the source filing. How we make and check alerts
Cynthia Smith bought 20,000 shares of Spero Therapeutics, Inc. ($SPRO) on June 23, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $SPRO is up 2.8% after 1 week, down 46.0% after 1 month and down 48.8% to date (from the $2.15 close on Jun 23, 2026).
SPRO
Spero Therapeutics, Inc.
Key Points
- Cynthia Smith bought 20,000 shares of Spero Therapeutics (SPRO) on June 23, 2026, valued at about $40,400 based on the current price of $2.02.
- The stock has traded between $1.08 and $3.08 over the past year, currently sitting at $2.02, indicating a potential opportunity for growth.
- Analysts maintain a positive outlook, with HC Wainwright & Co. recently raising its price target from $5.00 to $6.00 while keeping a Buy rating.
Get $SPRO trade alerts by text
We text you when insiders, Congress or big funds trade $SPRO. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Spero Therapeutics, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Spero Therapeutics, Inc.
Cynthia Smith purchased 20,000 shares of Spero Therapeutics (SPRO) on June 23, 2026, at a price of $2.02 per share. This purchase amounts to a total value of about $40,400. Smith's acquisition adds to a series of insider transactions occurring on the same day, reflecting a growing confidence among company leaders in the future of Spero Therapeutics.
Other Insiders Join the Trend
On the same day, several other insiders also made notable purchases. Kathleen Tregoning bought 10,000 shares, while Frank Thomas and Milind Deshpande each acquired 20,000 shares. Vink Patrick V.J.J. and John Pottage Jr. also participated, with Tregoning making another buy of 10,000 shares. This collective activity suggests a strong belief in the company's direction.
Stock Performance and Market Context
Spero Therapeutics has seen its stock fluctuate between $1.08 and $3.08 over the past year. The shares are currently trading at $2.02, which is above the 50-day moving average of $1.26 but below the 200-day moving average of $2.16. This context may signal potential for growth, especially with the recent influx of insider buying.
Analysts Set New Price Targets
Analysts are optimistic about Spero Therapeutics' future. On September 14, 2026, HC Wainwright & Co. maintained a Buy rating and raised its price target from $5.00 to $6.00. This reflects a positive sentiment towards the company's prospects, especially in light of its focus on developing treatments for multi-drug resistant bacterial infections.
What Spero Therapeutics, Inc. Does
Spero Therapeutics, based in Cambridge, Massachusetts, develops innovative treatments for challenging bacterial infections and rare diseases. Their key product candidates include an oral antibiotic designed to treat complicated urinary tract infections. The recent insider purchases indicate a strong belief in the company's ongoing projects and potential.
What to Watch at Spero Therapeutics, Inc.
Investors will be watching for Spero Therapeutics' next earnings report scheduled for November 12, 2026. The recent insider transactions should be viewed with the understanding that they reflect past performance and may not represent future trends. As always, it's important to stay informed about any further developments and filings from the company.
Related Filing Alerts
Source: Cynthia Smith's Form 4 filing on $SPRO (Jun 23, 2026). Find the original filing: SPRO Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts